Disease Overview：Mitral stenosis（MS）
Mitral stenosis is a valvular heart disease characterized by narrowing of the mitral valve orifice, most commonly due to rheumatic heart disease—though calcific degeneration, congenital anomalies, or systemic conditions like lupus may also contribute. This restriction impedes left atrial outflow into the left ventricle during diastole, leading to elevated left atrial pressure, pulmonary venous congestion, and eventually pulmonary hypertension and right heart strain. Symptoms often include dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea, fatigue, palpitations, and in advanced cases, hemoptysis or thromboembolic events such as stroke due to atrial fibrillation–associated left atrial appendage thrombus formation. Diagnosis relies on echocardiography (particularly transesophageal echo for detailed morphology and pressure gradient quantification), electrocardiography, chest radiography, and occasionally cardiac MRI or catheterization for hemodynamic assessment. Management ranges from pharmacologic control of rhythm and anticoagulation to interventional strategies—including percutaneous balloon mitral valvuloplasty (PBMV) for suitable anatomical profiles—or surgical options like mitral valve repair or replacement.
China offers distinct advantages for international patients seeking treatment: its cardiovascular centers—many accredited by international bodies such as JCI—house world-class interventional cardiologists and cardiac surgeons with extensive experience in complex valvular interventions. Advanced imaging platforms (3D/4D echocardiography, high-resolution CT angiography) and robotic-assisted or minimally invasive surgical systems ensure precision and reproducibility. Clinical outcomes align with global benchmarks: PBMV success rates exceed 90% in carefully selected patients, and surgical mortality for mitral valve procedures remains below 2% in top-tier hospitals. Crucially, costs are typically 40–60% lower than in the US or Western Europe—without compromising quality—making high-standard care highly accessible. As a dedicated medical tourism agency, we facilitate seamless access for international patients: verifying hospital credentials, coordinating specialist consultations, arranging visa support and accommodation, providing transparent, all-inclusive pricing upfront, and offering end-to-end bilingual assistance—from pre-travel evaluation to post-discharge follow-up.
Mitral stenosis: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Mitral Stenosis (Cardiovascular Department)
Non-Surgical / Conservative Management
*Indicated for asymptomatic or mild symptomatic patients (NYHA Class I–II), preserved left ventricular function, and valve area >1.5 cm².*
- •Medications:
- Beta-blockers or non-DHP CCBs (e.g., metoprolol, diltiazem): $6–$10/month - Anticoagulation (warfarin or DOACs): Warfarin $4–$7/month, rivaroxaban/apixaban $45–$65/month
- •Monitoring:
- ECG + Holter monitoring: $25–$40 - BNP/NT-proBNP + coagulation panel: $35–$50 - Annual follow-up clinic visit (cardiology): $22–$30
Surgical & Interventional Procedures
*Eligibility requires symptomatic moderate–severe stenosis (valve area ≤1.5 cm², mean gradient ≥10 mmHg), suitable valve morphology (Wilkins score ≤8), and absence of severe calcification or mitral regurgitation >2+.
- •Percutaneous Balloon Mitral Valvuloplasty (PBMV):
- Procedure (including balloon catheter, fluoroscopy, anesthesia): $3,200–$4,100 - 2-day hospital stay: $480–$650
- •Surgical Mitral Valve Replacement (MVR):
- Mechanical valve (e.g., St. Jude): $4,900–$5,800 - Bioprosthetic valve (e.g., Edwards SAPIEN, Perceval): $7,400–$9,200 - Surgery + 5-day ICU/stay: $8,600–$11,300
Special/Complex Scenarios
- •Severe calcification + atrial fibrillation + thrombus: Requires pre-op anticoagulation ≥3 months + transesophageal echo-guided thrombus clearance → adds $220–$350 (TEE repeat) + $180–$260 (extended anticoagulation monitoring).
- •Concomitant coronary artery bypass grafting (CABG): Adds $4,300–$5,700 to MVR cost.
- •Re-do surgery (prior sternotomy): Increases operative time and risk → adds $2,100–$3,000 to base MVR cost.
Quick Selection Guide
- •Age <65, Wilkins ≤8, no AF/thrombus: PBMV — lowest cost ($4,100 avg), fastest recovery, avoids lifelong anticoagulation.
- •Age ≥65, bioprosthetic preference, or contraindication to PBMV: Bioprosthetic MVR — avoids warfarin but higher upfront cost ($16,500 avg); ideal for limited life expectancy or bleeding risk.
- •Young adult with rheumatic MS + high thromboembolic risk: Mechanical MVR — durable, cost-effective long-term ($14,200 avg), despite lifelong anticoagulation.
- •Budget-constrained, NYHA II, stable: Conservative management — $200–$300/year; delay intervention until symptom progression confirmed by serial echo.
- •Comorbidities (COPD, renal failure): Prioritize PBMV over surgery unless anatomy prohibits it — reduces perioperative mortality and ICU dependency.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Mitral stenosis Medical Vacation Packages
Curated transparent all-inclusive packages combining Mitral stenosis treatment with China top medical destinations:
